Cargando…

Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience

Ovarian cancer is the most lethal gynecological cancer, and despite years of research, with the exception of a BRCA mutation driving the use of PARP inhibitors, no new prognostic/predictive biomarkers are clinically available. Improvement in biomarker selection and validation may derive from the sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Califano, Daniela, Russo, Daniela, Scognamiglio, Giosuè, Losito, Nunzia Simona, Spina, Anna, Bello, Anna Maria, Capiluongo, Anna, Galdiero, Francesca, De Cecio, Rossella, Bevilacqua, Simona, Gargiulo, Piera, Marchesi, Edoardo, Canevari, Silvana, Perrone, Francesco, Daniele, Gennaro, De Cecco, Loris, Mezzanzanica, Delia, Pignata, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226822/
https://www.ncbi.nlm.nih.gov/pubmed/32272732
http://dx.doi.org/10.3390/cells9040903
_version_ 1783534370205728768
author Califano, Daniela
Russo, Daniela
Scognamiglio, Giosuè
Losito, Nunzia Simona
Spina, Anna
Bello, Anna Maria
Capiluongo, Anna
Galdiero, Francesca
De Cecio, Rossella
Bevilacqua, Simona
Gargiulo, Piera
Marchesi, Edoardo
Canevari, Silvana
Perrone, Francesco
Daniele, Gennaro
De Cecco, Loris
Mezzanzanica, Delia
Pignata, Sandro
author_facet Califano, Daniela
Russo, Daniela
Scognamiglio, Giosuè
Losito, Nunzia Simona
Spina, Anna
Bello, Anna Maria
Capiluongo, Anna
Galdiero, Francesca
De Cecio, Rossella
Bevilacqua, Simona
Gargiulo, Piera
Marchesi, Edoardo
Canevari, Silvana
Perrone, Francesco
Daniele, Gennaro
De Cecco, Loris
Mezzanzanica, Delia
Pignata, Sandro
author_sort Califano, Daniela
collection PubMed
description Ovarian cancer is the most lethal gynecological cancer, and despite years of research, with the exception of a BRCA mutation driving the use of PARP inhibitors, no new prognostic/predictive biomarkers are clinically available. Improvement in biomarker selection and validation may derive from the systematic inclusion of translational analyses into the design of clinical trials. In the era of personalized medicine, the prospective centralized collection of high-quality biological material, expert pathological revision, and association to well-controlled clinical data are important or even essential added values to clinical trials. Here, we present the academic experience of the MITO (Multicenter Italian Trial in Ovarian Cancer) group, including gynecologists, pathologists, oncologists, biostatisticians, and translational researchers, whose effort is dedicated to the care and basic/translational research of gynecologic cancer. In our ten years of experience, we have been able to collect and process, for translational analyses, formalin-fixed, paraffin-embedded blocks from more than one thousand ovarian cancer patients. Standard operating procedures for collection, shipping, and processing were developed and made available to MITO researchers through the coordinating center’s web-based platform. Clinical data were collected through dedicated electronic case report forms hosted in a web-based electronic platform and stored in a central database at the trial’s coordinating center, which performed all the analyses related to the proposed translational researches. During this time, we improved our strategies of block management from retrospective to prospective collection, up to the design of a prospective collection with a quality check for sample eligibility before patients’ accrual. The final aim of our work is to share our experience by suggesting a guideline for the process of centralized collection, revision processing, and storing of formalin-fixed, paraffin-embedded blocks for translational purposes.
format Online
Article
Text
id pubmed-7226822
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72268222020-05-18 Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience Califano, Daniela Russo, Daniela Scognamiglio, Giosuè Losito, Nunzia Simona Spina, Anna Bello, Anna Maria Capiluongo, Anna Galdiero, Francesca De Cecio, Rossella Bevilacqua, Simona Gargiulo, Piera Marchesi, Edoardo Canevari, Silvana Perrone, Francesco Daniele, Gennaro De Cecco, Loris Mezzanzanica, Delia Pignata, Sandro Cells Article Ovarian cancer is the most lethal gynecological cancer, and despite years of research, with the exception of a BRCA mutation driving the use of PARP inhibitors, no new prognostic/predictive biomarkers are clinically available. Improvement in biomarker selection and validation may derive from the systematic inclusion of translational analyses into the design of clinical trials. In the era of personalized medicine, the prospective centralized collection of high-quality biological material, expert pathological revision, and association to well-controlled clinical data are important or even essential added values to clinical trials. Here, we present the academic experience of the MITO (Multicenter Italian Trial in Ovarian Cancer) group, including gynecologists, pathologists, oncologists, biostatisticians, and translational researchers, whose effort is dedicated to the care and basic/translational research of gynecologic cancer. In our ten years of experience, we have been able to collect and process, for translational analyses, formalin-fixed, paraffin-embedded blocks from more than one thousand ovarian cancer patients. Standard operating procedures for collection, shipping, and processing were developed and made available to MITO researchers through the coordinating center’s web-based platform. Clinical data were collected through dedicated electronic case report forms hosted in a web-based electronic platform and stored in a central database at the trial’s coordinating center, which performed all the analyses related to the proposed translational researches. During this time, we improved our strategies of block management from retrospective to prospective collection, up to the design of a prospective collection with a quality check for sample eligibility before patients’ accrual. The final aim of our work is to share our experience by suggesting a guideline for the process of centralized collection, revision processing, and storing of formalin-fixed, paraffin-embedded blocks for translational purposes. MDPI 2020-04-07 /pmc/articles/PMC7226822/ /pubmed/32272732 http://dx.doi.org/10.3390/cells9040903 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Califano, Daniela
Russo, Daniela
Scognamiglio, Giosuè
Losito, Nunzia Simona
Spina, Anna
Bello, Anna Maria
Capiluongo, Anna
Galdiero, Francesca
De Cecio, Rossella
Bevilacqua, Simona
Gargiulo, Piera
Marchesi, Edoardo
Canevari, Silvana
Perrone, Francesco
Daniele, Gennaro
De Cecco, Loris
Mezzanzanica, Delia
Pignata, Sandro
Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience
title Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience
title_full Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience
title_fullStr Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience
title_full_unstemmed Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience
title_short Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience
title_sort ovarian cancer translational activity of the multicenter italian trial in ovarian cancer (mito) group: lessons learned in 10 years of experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226822/
https://www.ncbi.nlm.nih.gov/pubmed/32272732
http://dx.doi.org/10.3390/cells9040903
work_keys_str_mv AT califanodaniela ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT russodaniela ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT scognamigliogiosue ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT lositonunziasimona ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT spinaanna ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT belloannamaria ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT capiluongoanna ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT galdierofrancesca ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT dececiorossella ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT bevilacquasimona ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT gargiulopiera ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT marchesiedoardo ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT canevarisilvana ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT perronefrancesco ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT danielegennaro ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT dececcoloris ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT mezzanzanicadelia ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience
AT pignatasandro ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience